About nContact
nContact is a Healthcare company based in Morrisville (United States) founded in 2005, and was acquired by AtriCure in October 2015. Epicardial ablation devices. nContact has raised $67.67 million across 8 funding rounds from investors including AtriCure, Hercules Capital and Harbert Management. The company has 14 employees. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is NCONTACT SURGICAL, INC. Its competitors include AtriCure, AtaCor Medical and Kestra Medical Technologies; 2 of its 3 listed competitors have raised funding.
Company details
nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.
- Headquarters Morrisville, United States
- Employees 14
- Stage Acquired
- SectorsHealthcare
- Website ncontact.us
- Acquired by AtriCure (Oct 2015)
- Legal Name Ncontact Surgical, Inc.
Funding Insights of nContact
nContact has successfully raised a total of $67.67M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $20 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67.67M
- Total Rounds 8
- Last Round Series D β $20M
- First Round $7.5M
(Sep 2006)
- Investors Count 7
All 8 funding rounds of nContact with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $20M | Series D | β | β | |
| Mar 2013 | $6.74M | Series D | β | β | β |
| Jan 2012 | $433,761 | Debt – Conventional | β | β | β |
| Nov 2010 | $16.15M | Series C | β | β | |
| Aug 2010 | $4M | Series C | β | β | β |
| Apr 2009 | $4.79M | Series B | β | β | β |
| Nov 2007 | $8.5M | Series B | β | β | β |
| Sep 2006 | $7.5M | Series A | β | β |
8 investors in total: 8 institutional.
Investors in nContact
nContact has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include AtriCure, Hercules Capital and Harbert Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors | 1993 | harbert.net | Birmingham, United States | |
| finistere.com | ||||
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
| masseyburch.com | ||||
Seed and early stage tech and life sciences focused VC firm funding companies in the US and Europe | talloakscapital.com | Charlottesville, United States | ||
FinTech & Media focused seed and early stage VC firm investing in the US | villageventures.com | Williamstown, United States | ||
Cardiac ablation and occlusion devices for atrial fibrillation are provided. | 2000 | atricure.com | Mason, United States |
Investor details for nContact
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of nContact
4 dated milestones of nContact across 10 years, from founding to its latest funding, stage changes and deals.
- Founded nContact is founded.
- Funding First funding round of $7.5M.
- Funding Latest funding round, Series D, of $20.0M.
- Exit Acquired by AtriCure.
Competitors of nContact
nContact has 3 listed competitors in our database, 2 of them funded. They include AtriCure, AtaCor Medical and Kestra Medical Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atricure.com | 2000 | Mason, United States | 1,874 | Cardiac ablation and occlusion devices for atrial fibrillation are provided. | ||
| atacor.com | 2014 | San Clemente, United States | $136.8M | 15 | An implantable pacemaker system is developed for cardiac pacing therapy. | |
| kestramedical.com | 2014 | Kirkland, United States | $196M | 118 | Medical devices are developed to support cardiovascular patients at risk. |
Detailed competitors of nContact
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as nContact (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about nContact
nContact was founded in 2005 and raised its 1st funding round 1 year after it was founded.
nContact is headquartered in Morrisville, United States.
nContact is a funded company, having raised a total of $67.67M across 8 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on Sep 2006.
nContact has 14 employees.
nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.
nContact's top competitors include AtaCor Medical, AtriCure and Kestra Medical Technologies.
nContact has 8 investors. Key investors include AtriCure, Hercules Capital, Harbert Management, Finistere Ventures, and Intersouth Partners.
nContact operates through Ncontact Surgical, Inc..
Yes. nContact was acquired by AtriCure in October 2015.
